"Immunoglobulin M" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A class of immunoglobulin bearing mu chains (IMMUNOGLOBULIN MU-CHAINS). IgM can fix COMPLEMENT. The name comes from its high molecular weight and originally being called a macroglobulin.
| Descriptor ID |
D007075
|
| MeSH Number(s) |
D12.776.124.486.485.114.619.574 D12.776.124.790.651.114.619.574 D12.776.377.715.548.114.619.574
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Immunoglobulin M".
Below are MeSH descriptors whose meaning is more specific than "Immunoglobulin M".
This graph shows the total number of publications written about "Immunoglobulin M" by people in this website by year, and whether "Immunoglobulin M" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 2 | 2 | 4 |
| 1996 | 1 | 2 | 3 |
| 1997 | 0 | 3 | 3 |
| 1998 | 0 | 1 | 1 |
| 1999 | 1 | 1 | 2 |
| 2000 | 0 | 3 | 3 |
| 2001 | 0 | 2 | 2 |
| 2002 | 0 | 4 | 4 |
| 2004 | 0 | 2 | 2 |
| 2005 | 0 | 5 | 5 |
| 2006 | 2 | 2 | 4 |
| 2007 | 0 | 3 | 3 |
| 2008 | 0 | 3 | 3 |
| 2009 | 1 | 3 | 4 |
| 2010 | 0 | 3 | 3 |
| 2011 | 0 | 3 | 3 |
| 2012 | 0 | 2 | 2 |
| 2013 | 2 | 5 | 7 |
| 2014 | 2 | 5 | 7 |
| 2015 | 0 | 5 | 5 |
| 2016 | 0 | 3 | 3 |
| 2017 | 5 | 6 | 11 |
| 2018 | 3 | 5 | 8 |
| 2019 | 1 | 3 | 4 |
| 2020 | 1 | 7 | 8 |
| 2021 | 0 | 5 | 5 |
| 2022 | 0 | 3 | 3 |
| 2023 | 0 | 5 | 5 |
| 2024 | 0 | 4 | 4 |
| 2025 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Immunoglobulin M" by people in Profiles.
-
Characterizing local antibody responses in the muscle of inclusion body myositis patients. J Autoimmun. 2025 Jun; 154:103437.
-
Development of a Shigella conjugate vaccine targeting Shigella flexneri 6 that is immunogenic and provides protection against virulent challenge. Vaccine. 2024 10 24; 42(24):126263.
-
Malaria and other infections induce polyreactive antibodies that impact SARS-CoV-2 seropositivity estimations in endemic settings. J Med Virol. 2024 06; 96(6):e29713.
-
Unswitched memory B cell deficiency in children with sickle cell disease and response to pneumococcal polysaccharide vaccine. Am J Hematol. 2024 06; 99(6):1084-1094.
-
Antigen-independent, autonomous B cell receptor signaling drives activated B cell DLBCL. J Exp Med. 2024 May 06; 221(5).
-
Persistence of dengue serotype 2 viral RNA in blood cells of a returned traveler with dengue fever. Travel Med Infect Dis. 2024 May-Jun; 59:102699.
-
Distinct patterns of auto-reactive antibodies associated with organ-specific immune-related adverse events. Front Immunol. 2023; 14:1322818.
-
Peptidylarginine deiminase 2 citrullinates MZB1 and promotes the secretion of IgM and IgA. Front Immunol. 2023; 14:1290585.
-
Colistin resistance mutations in phoQ can sensitize Klebsiella pneumoniae to IgM-mediated complement killing. Sci Rep. 2023 08 03; 13(1):12618.
-
SARS-CoV-2 vaccine breakthrough infections (VBI) by Omicron variant (B.1.1.529) and consequences in structural and functional impact. Cell Signal. 2023 09; 109:110798.